

# Journal of Visualized Experiments

## Discovery of Metastatic Regulators Using a Rapid and Quantitative Intravital Chick Chorioallantoic Membrane Model

--Manuscript Draft--

Article Type:	Invited Methods Collection - JoVE Produced Video
Manuscript Number:	JoVE62077R1
Full Title:	Discovery of Metastatic Regulators Using a Rapid and Quantitative Intravital Chick Chorioallantoic Membrane Model
Corresponding Author:	Konstantin Stoletov CANADA
Corresponding Author's Institution:	
Corresponding Author E-Mail:	kstoletov@gmail.com
Order of Authors:	Konstantin Stoletov Lian Willetts Perrin Beatty John Lewis
Additional Information:	
Question	Response
Please specify the section of the submitted manuscript.	Cancer Research
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the <b>city, state/province, and country</b> where this article will be <b>filmed</b> . Please do not use abbreviations.	Edmonton, Alberta, Canada
Please confirm that you have read and agree to the terms and conditions of the author license agreement that applies below:	I agree to the <a href="#">Author License Agreement</a>
Please provide any comments to the journal here.	

**TITLE:**

Discovery of Metastatic Regulators Using a Rapid and Quantitative Intravital Chick Chorioallantoic Membrane Model

**AUTHORS AND AFFILIATIONS:**

Konstantin Stoletov<sup>1</sup>, Lian Willetts<sup>2</sup>, Perrin H. Beatty<sup>3</sup>, John D. Lewis<sup>1</sup>

<sup>1</sup>Department of Oncology, University of Alberta, Edmonton, Alberta, Canada.

<sup>2</sup>Department of Cell Biology & Anatomy, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

<sup>3</sup>Entos Pharmaceuticals, 4550 - 10230 Jasper Avenue, Edmonton, Alberta, Canada, T5J 4P6.

Corresponding Author:

John D. Lewis ([jdlewis@ualberta.ca](mailto:jdlewis@ualberta.ca))

Email Addresses of Co-Authors

Konstantin Stoletov ([kstoletov@gmail.com](mailto:kstoletov@gmail.com))

Lian Willetts ([lian.willetts@ucalgary.ca](mailto:lian.willetts@ucalgary.ca))

Perrin H. Beatty ([pbeatty@ualberta.ca](mailto:pbeatty@ualberta.ca))

**KEYWORDS:**

cancer metastasis, chorioallantoic membrane, compact colony, intravital screening, intravital imaging, invasive metastatic colony, metastasis suppressors

**SUMMARY:**

This is an effective method to screen for suppressors or drivers of cancer metastasis. Cells, transduced with an expression library, are injected into the chicken chorioallantoic membrane vasculature to form metastatic colonies. Colonies having decreased or increased invasiveness are excised, expanded, reinjected to confirm their phenotype, and finally, analyzed using high throughput sequencing.

**ABSTRACT:**

Recent advances in cancer research has illustrated the highly complex nature of cancer metastasis. Multiple genes or genes networks have been found to be involved in differentially regulating cancer metastatic cascade genes and gene products dependent on the cancer type, tissue, and individual patient characteristics. These represent potentially important targets for genetic therapeutics and personalized medicine approaches. The development of rapid screening platforms is essential for the identification of these genetic targets.

The chick chorioallantoic membrane (CAM) is a highly vascularized, collagen rich membrane located under the eggshell that allows for gas exchange in the developing embryo. Due to the location and vascularization of the CAM, we developed it as an intravital human cancer metastasis model that allows for robust human cancer cell xenografting and real-time imaging of cancer cell interactions with the collagen rich matrix and vasculature.

Using this model, a quantitative screening platform was designed for the identification of novel drivers or suppressors of cancer metastasis. We transduced a pool of head and neck HEP3 cancer cells with a complete human genome shRNA gene library, then injected the cells, at low density, into the CAM vasculature. The cells proliferated and formed single-tumor cell colonies. Individual colonies that were unable to invade into the CAM tissue were visible as a compact colony phenotype and excised for identification of the transduced shRNA present in the cells. Images of individual colonies were evaluated for their invasiveness. Multiple rounds of selections were performed to decrease the rate of false positives. Individual, isolated cancer cell clones or newly engineered clones that express genes of interest were subjected to primary tumor formation assay or cancer cell vasculature co-option analysis. In summary we present a rapid screening platform that allows for anti-metastatic target identification and intravital analysis of a dynamic and complex cascade of events.

## **INTRODUCTION:**

Metastasis is the main cause of cancer patient death<sup>1-3</sup>. Metastatic cancer cells utilize distinct signaling pathways, dependent on the type of cancer, throughout the five steps of the metastatic cascade: local invasion, intravasation, survival in the circulation, extravasation, and colony expansion at distant metastatic sites. Current understanding of this metastatic process suggests that there are two bottleneck steps, one is directional invasion of the cancer cell from the primary tumor, and the second is the establishment of the distant site metastatic lesion<sup>4-6</sup>. Both steps require cancer cells to actively interact with collagen and vasculature at the sites of initial invasion or distant metastatic lesion formation. Therefore, metastatic cancer cells must be able to attach to cells, remodel collagen fibers, and directionally invade along vascular walls<sup>7</sup>. Screening models that can rapidly identify antimetastatic therapeutic targets to block cancer cells from completing these steps is of the highest importance. Existing in vitro screening models do not fully mimic the complex live tissue environment. Mouse models are costly and time consuming. Therefore, there is an urgent need for intravital screening platforms that provide complex live tissue environments and rapid identification of targets.

Within the last decade, the chicken embryo has been established as a robust and cost-effective model of human cancer metastasis<sup>8-12</sup>. The chick chorioallantoic membrane (CAM) tissue is thin and translucent which makes it ideal for intravital microscopic imaging of cell and colony behaviors in primary tumor and/or metastatic sites<sup>12</sup>. Primary tumor growth from multiple human cancer cell lines can be initiated and metastasized within a span of only several days after microinjection into the CAM tissue. Cancer cells can be administered into the CAM tissue in several ways, including intravenously, intra-CAM or as collagen onplants, this flexibility allows the researcher to focus on specific stages of cancer progression, for example, metastatic lesion formation, invasion out of the primary tumor or angiogenesis.

Here we describe a quantitative screening platform that can be used to measure the ability of cancer cells to establish invasive metastatic lesions. Cancer cells that have been transduced with an expression library are injected intravenously into the CAM vasculature at low density. Metastatic colonies form for 4-5 days, then the invasion capacity and vasculature interaction of

the resulting colonies is evaluated. Individual colonies that fail to invade are excised, propagated and their phenotype is confirmed in the CAM by reinjection and quantification of colony compactness and cancer cell-blood vessel contacts. The expression library constructs responsible for the single metastatic colony mutant phenotype are identified from isolated colony genomic DNA via high throughput sequencing. The same platform may be further used to validate the causal link between a gene and the observed phenotype or to perform in-depth mechanistic studies on the observed phenotype.

#### **PROTOCOL:**

All experiments were performed in accordance with the regulations and guidelines of the Institutional Animal Care and Use Committee at the University of Alberta. Avian embryos are not considered to be live animals by many research institutes and no animal protocols are required. It is, however, an accepted view that avian embryos can feel pain and, therefore, must be treated as humanely as possible. The local animal research authority must be contacted prior commencing of any research work to ensure that proper regulations are followed.

#### **1. Shell-less egg culture**

1.1. Acquire fertilized chicken eggs from the local provider. This experiment uses White Leghorn chicken breed; however, other breeds can be used as well.

NOTE: It is recommended to acquire 10% more eggs than needed in case some of the embryos are damaged during the cracking and cannot be used in this protocol.

1.2. Transfer the required number of eggs into a 60% humidified rocking incubator. The rest of the eggs can be stored for up to two weeks at 12 °C without loss of viability.

1.3. Incubate the eggs in the humidified rocking incubator for four days.

NOTE: Day 1 is when the eggs are transferred to the rocking incubator.

1.3. Prepare the weighing dishes and plastic lids for the shell-less egg culture. Cut one of the corners of each of the weighing dishes to allow for efficient air access to the embryo (**Figure 1A**).

1.4. Arrange the prepared weighing dishes in rows in the flow hood. (**Figure 1B**).

1.5. In a separate weighing dish prepare 70% ethanol for egg rinsing.

1.6. Briefly dip the egg in 70% ethanol, then use the electric rotary tool to carefully make four 2-3 mm cuts parallel to the largest latitudinal diameter of the egg (**Figure 1C**).

1.7. Transfer the cut egg into a weighing dish and gently press the egg against the dish bottom until a crack forms in the eggshell (**Figure 1D**).

1.8. Pull the eggshell halves apart letting the embryo slip into the weighing dish. Discard the eggshell and cover the weighing dish with a lid.

1.9. Transfer the embryos into humidified non rocking incubator (**Figure 1E**).

NOTE: Weighing dishes containing the embryos are placed into separate plastic containers (12 embryos/container). This increases embryo viability and allows for experiment-specific embryo organization.

1.10. Incubate embryos for 6 more days (until 10 days old). Check for dead or contaminated embryos daily and remove them from the incubator.

NOTE: Embryos can be contaminated by airborne mold spores. Mold contamination initially manifests as white speckles on the embryo CAM surface. Remove the contaminated embryos immediately and wipe the incubator with 70% ethanol on weekly basis to prevent the contamination. In our experience contamination levels are very low ~1-3%.

1.11. Use these embryos for cancer cell injection in the morning of day 10.

## 2. Preparation of the cancer cells for injection

NOTE: Metastatic colony selection is based on a phenotype established by fluorescent cancer cells, derived from an expression library or vector tagged with fluorescent protein such as green or red fluorescent protein (see the whole screen flow in **Figure 2A**). It is not recommended to use cells transiently transfected with fluorescent proteins or labeled with cell permeable fluorescent dyes due to rapid fading of signal caused by cancer cell proliferation and uneven staining.

2.1. Culture cancer cells to 60-70% confluency at the time of injection. Using cancer cells at higher levels of confluency will decrease their viability, resulting in low efficiency of metastatic colony formation. Ensure that the cancer cells used are mycoplasma free since mycoplasma contamination may lead to decreased chicken embryo viability.

2.2. Rinse cells twice with 1x PBS pH 7.4. Remove the remaining PBS, then add 0.5% Trypsin-EDTA and incubate at 37 °C for 2–5 min until all cells are lifted from the culture dish surface.

2.3. Transfer the cell suspension into 15 mL conical tube and centrifuge cells at room temperature at 200 x *g* for 5 min.

2.4. Resuspend cells in 10 mL of PBS to and centrifuge the cells again as in step 2.3, to remove trypsin and other culture media components such as antibiotics.

NOTE: Presence of trypsin or cell culture components such as antibiotics in the cancer cell suspension may result in decreased chicken embryo viability.

2.5. Carefully aspirate the supernatant and resuspend cells with 1 mL of ice-cold PBS.

2.6. Count the number of cells using a hemocytometer or any other cell counting equipment available.

NOTE: This screening protocol requires that each metastatic colony be initiated by a single cell. When counting the cells make sure that the cells are fully trypsinized and exist as a single cell suspension (no cell clumps are present).

2.7. For intravenous (IV) injection concentrate cells to  $0.5 \times 10^6$  to  $1.0 \times 10^6$  cells/mL. Use ice cold 1x PBS to dilute and/or resuspend cell concentrates. Expect that approximately 1 mL of cells suspension will be needed for every ten embryos.

NOTE: Necessary cell suspension concentration in suspension is mainly determined by the level of experimenter experience. Please see next section for more details.

### 3. Intravenous injection of cancer cells for metastatic colony formation

NOTE: Following this protocol as many as a hundred of embryos can be injected within one day. It generally takes longer time to isolate the metastatic colonies (Step 5) then to inject the cancer cells and, therefore, it is recommended to perform an initial experiment to estimate the time needed to complete all the steps. Using differential cancer cell fluorescent labels helps to reduce animal numbers and the time required for each experiment. For example, control cells can be labeled with RFP (red fluorescent protein) while mutant tumor cells can be alternatively labeled with GFP (green fluorescent protein). In this case, each experiment has a built-in control that corrects for inter-embryo variability.

3.1 Assemble the injection apparatus as it shown on **Figure 2B**. First mount a needle onto the syringe and then extend the syringe needle with 3-5 cm long piece of tubing.

3.2. Break the tip of the borosilicate needle off using the fine forceps (~20-60  $\mu$ L wide).

3.3. Load the syringe with the cancer cell suspension (50-200  $\mu$ L) and insert the borosilicate needle into the tubing (**Figure 2B**).

3.4. Inspect the borosilicate needle for cell clogging and air bubbles. It is critical to inject cells as a single cell suspension to ensure that each metastatic colony is initiated by a single cell.

NOTE: Cancer cells tend to aggregate in PBS within 1-2 h post trypsinization and, therefore, should be prepared immediately before injection. If necessary, cells can be resuspended periodically using the 1 mL syringe used for injections (without the borosilicate needle).

3.5. If cell clogging is observed within the capillary, remove the capillary, re-suspend the cells, and replace it with a new capillary. Use the plunger to push out any bubbles. If no cell clogging

or bubbles are observed proceed to the next step.

3.6. Remove the cover lid and transfer the embryo under the stereoscope. Identify the appropriate vein to be injected on the CAM surface. Veins and arteries form the intricate network within the CAM tissue (**Figure 2C**). Veins are distinguished by the brighter red color because they carry oxygen rich blood to the embryo.

NOTE: For general embryo manipulation, cancer cell injection and metastatic colony excision, use a fluorescent stereomicroscope equipped with 0.8x and 1.5x objectives and 10x eyepieces for visualization. Less advanced microscope can also be successfully used for these procedures, depending on the users' experience level. Readers can contact the authors for more detailed recommendations.

3.7. Find the ideal vein to inject cells which is normally only slightly wider (10-20%) than the diameter of borosilicate needle tip and located midway between the embryo and the weighing dish wall. It is generally easier to inject at the point immediately adjacent to the vein bifurcation.

NOTE: Injection into a larger vein may appear easier but will lead to excessive bleeding and decreased embryo survival.

3.8. Press the tip of the needle against the blood vessel wall and apply gentle pressure in the same direction as the blood flow. If necessary, use a cotton swab (held in other hand) to help anchor or stabilize the vessel that is being injected.

3.9. Gently depress the syringe plunger. One can visualize a successful injection by observing a "clearing" of the blood vessel when the cancer cell suspension enters the blood stream.

3.10. Continue depressing the syringe plunger for 2-10 s until the desired suspension volume is injected into the blood stream of the vein. All together the injection of a single embryo may require 1–10 min depending on the experience level of the user. If excessive bleeding or clear liquid accumulation appears at the injection site, discard the embryo.

NOTE: It is easy to "over-inject" an embryo. The general consideration that should be kept in mind is that metastatic colonies should not touch each other after a 4-5 days growth period. Ideally ~5-10% of terminal CAM vein capillaries should have cells immobilized in them after a successful injection (**Figure 2D,E**). As mentioned in the step 2, a range of cell concentration can be used ( $0.5 \times 10^6$  -  $1.0 \times 10^6$  cells/mL). Lower concentrations will require longer injection time but will decrease the needle clogging. Higher concentrations will require shorter injection times but will increase the needle clogging. It is recommended to try several concentrations to find the one that is most comfortable for an operator. Generally, higher concentration ( $1.0 \times 10^6$  cells/mL) is preferred to decrease the injection time.

3.11. Remove the needle from the CAM and gently dab the injection site with a cotton swab to remove any blood or excess cancer cells.

3.12. Cover the embryo in the weighing dish with a lid and return the injected chicken embryo into the incubator.

3.13. Repeat the procedure with the next embryo until all embryos are injected.

#### **4. Embryo maintenance during the metastatic colony growth**

4.1. Visually inspect the embryos. If there are any that are dead, and/or contaminated with bacteria or mold remove them from the incubator, then autoclave and discard them according to laboratory disposal procedures.

NOTE: It is recommended that embryos are inspected every other day (days 1, 3, 5 post cancer cell injection) for metastatic colony growth. Avoid moving the injected embryos unnecessarily since it may cause embryo damage and/or death.

4.2. If cells display overgrowth (metastatic colonies overlap with each other) or uneven distribution within the CAM tissue (metastatic colonies located in small subarea of the CAM surface) remove that embryo from the experiment. Euthanize discarded embryos by freezing at -20 °C (or another approved method) immediately after removal from the experiment. The number of viable metastatic cells within the CAM tissue will decrease initially (days 1-2) and then increase (days 2-5).

NOTE: Some embryos may “reject” the cancer cells, i.e., all the cancer cells will disappear from the CAM tissue. These embryos should be removed from the experiment. Normally, cancer cell colonies can be seen through the transparent lid under the fluorescent stereo microscope without opening the weighing dish.

4.3. Ensure metastatic colonies appear uniform in shape (first 1-3 days post injection). Identify invasive or non-invasive metastatic colonies at days 4-5 post injection (see Section 5 for more details).

#### **5. Isolation of metastatic colonies**

5.1. At day 5 post injection remove embryos from incubator and inspect the embryo CAMs for metastatic colony distribution. Identify the embryos with uniform colony distribution in which compact (or overly invasive) colonies are present.

NOTE: The process of culturing chicken embryos is not sterile, therefore, all the screening steps must be performed under highly clean conditions to avoid future tissue culture contamination. Contamination is quite rare and can be easily avoided by wearing gloves and a mask and using only sterile tools during cell injection and colony isolation procedures. It is recommended to inspect embryos one by one to decrease their exposure to the ambient laboratory temperature and to prevent contamination.



5.2. Locate the metastatic colony of interest. A compact colony can be described as one with most of the cancer cells located within a limited area in the CAM tissue (cells appear “clumped together”). An invasive colony can be described as colony where cancer cells “scatter” in the CAM tissue (Figure 3A,B).

NOTE: “Compactness” of the metastatic colony can be explained either by the inhibition of cancer cell invasion, inhibition of cancer cell proliferation, or both. Attention should be paid to all scenarios and contact colonies should be isolated (Figure 3A,B). A simple fluorescent stereomicroscope can be used to discriminate between compact and invasive metastatic colony phenotypes.

5.3. Under the dissection microscope gently pull the CAM tissue that contains the metastatic colony of interest upwards using fine forceps (Figure 3C).

5.4. Cut off the CAM tissue that contains the metastatic colony using surgical scissors.

5.5. Transfer the CAM tissue that contains the metastatic colony into an empty, sterile 1.5 mL tube (on ice) and close the tube lid.

NOTE: Isolated colonies can be kept on ice for up to 3 h without loss of viability.

5.6. Repeat the excision procedure until all the colonies of interest are collected into separate tubes. To avoid animal suffering, do not excise more than 2-3 colonies from one embryo. Euthanize embryos by freezing at -20 °C (or another approved method) immediately after the colony excision.

5.7. Gently mince the CAM tissue in a microcentrifuge tube using a sterile 18 G needle. Use a separate needle for each colony.

5.8. Add 100 µL of 1x collagenase solution and incubate for 30 min at 37 °C.

5.9. Spin down the cells and CAM tissue at 300 x g for 5 min at ambient temperature.

5.10. Aspirate the collagenase solution and resuspend cells in complete media used for the cell line of interest.

NOTE: Normally CAM tissue is not completely dissociated after collagenase treatment and cancer cells will first proliferate within the pieces of CAM tissue and only later migrate onto the tissue culture dish.

5.11. Spin the cells and CAM tissue again at 300 x g for 5 min at ambient temperature.

5.12. Resuspend cells and CAM tissue pieces in 1 mL of complete media plus selection factor (if any), then transfer into single 12 well tissue culture dish well.

NOTE: Chicken CAM fibroblasts may persist in tissue culture for multiple passages inhibiting clonal expansion. Ability to expand the metastatic colonies in the presence of selection factor (i.e., if a vector that was used to render cancer cells fluorescent also encodes a mammalian antibiotic resistance gene) may greatly speed up clonal expansion. A kill curve experiment should be performed before the screening to ensure that proper concentration of antibiotic is used.

5.13. For the next 1-3 weeks monitor cancer cells daily for growth and contamination.

5.14. When cells reach 70-80% of confluency transfer cells into a larger volume culture dish.

NOTE: It is recommended to expand cells till at least two cryogenic vials of each clone can be frozen. Maintaining large amounts of tissue culture can be laborious and unnecessary.

5.15. Proceed to sequencing or next round of selection as soon as enough cancer cell numbers are reached. Generally,  $1 \times 10^6$  of cancer cells are sufficient for modern high-throughput sequencing techniques.

5.16. Proceed to the clone reinjection and imaging and quantification of colony compactness or cancer cell-blood vessel contact (**Figure 2A**). Alternatively proceed to high throughput sequencing or repeat the colony selection.

NOTE: To decrease the number of false positives at least two rounds of selection is recommended. Two approaches have been successfully employed. 1) Expand each clone and reinject individually to confirm the colony phenotype. 2) Mix all the expanded clones in a 1:1 ratio each, reinject as a mixture and repeat the selection cycle.

## 6. Injection of fluorescently tagged lectins into the CAM vasculature.

6.1. Identify the vein to be injected. It is easier to use the same injection site for lectin that was used for tumor cell injection.

6.2. Dilute fluorescent lectin stock solution (5 mg/mL) 50-100x with 1x PBS and load it into the same injection apparatus as used for cancer cell injection.

NOTE: The amount of lectin that needs to be injected (normally 20-100  $\mu$ L) for blood vessel visualization is dependent on microscope sensitivity and should be determined experimentally before screening.

6.3. Inject lectin using the same technique as for tumor cell injection (see steps 3.6.-3.10.).

6.4. After the lectin injection, place the embryo into the incubator to recover for 5 min. Inject only one embryo at a time and immediately before imaging the embryo.

NOTE. Embryos that are 12 days or older generally recover well from the lectin injections and can

be reinjected with lectin again next day for sequential imaging. Younger embryos are more sensitive and may display blood coagulation.

## **7. Visualization of cancer cell-blood vessel contacts**

7.1. Set the temperature-regulated microscope enclosure to 37 °C approximately 6 h prior to imaging. This will stabilize microscope temperature and help minimize XYZ drift during imaging.

NOTE. A specialized chicken embryo imaging chamber<sup>9-13</sup> was used for this experiment. A simple fluorescent dissection microscope can be used for all the steps starting from cancer cell injection to clone selection and clone reinjection, and evaluation of the colony compactness. A confocal microscope that is equipped with an imaging chamber is necessary for imaging and quantification of cancer cell-blood vessel contacts. No heating is necessary for up to 1 h and generally embryos survive at least two sequential imaging sessions with no impact to their viability.

7.2. Ensure that the necessary objective lens (20x or 25x water immersion objective lens is recommended) has been installed.

7.3. Apply a thin layer of vacuum grease to underside of the imaging chamber lid to create a secure seal with the coverslip.

7.4. Gently position a coverslip into the lid and wipe away any excess vacuum grease.

7.5. Take the lectin injected embryo out of the incubator and cut the rims of the weighing dish if necessary.

7.6. Position the embryo in the imaging chamber with the coverslip lowered down directly onto the area of the CAM where the metastatic colonies of interest are located. Slowly lower the lid onto the embryo until the coverslip just contacts the CAM. Tighten the screws to secure the lid in place, ensure the lid is leveled and that the coverslip is not putting any downward pressure on the CAM.

7.7. Acquire images of multiple, random colonies from control and experimental groups (10-20) from several (5-10) embryos.

NOTE. Acquiring random 3D stacks (1-5um Z-steps; 50-100um range; 25x) from each field is recommended.

7.8. Use field-stitching option in the microscope acquisition software if available. Since images used for quantification will not be publication quality, use fast acquisition modes such as resonant scanning if available. Use 25x objective and 3 x 3 stitching with 5-10 µm Z-step, 100 µm total range. Image at least 100 cells (~20 colonies) per condition.

## **8. Quantification of cancer cell blood vessel contacts**

8.1. Open the 3D file as a Z-stack using the necessary software.

NOTE. Specialized software must be used to acquire and analyze high resolution images in order to quantify cancer cell-blood vessel contact. Several software packages that are capable of 3D image analysis are available. Please see **Table of Materials** for more details.

8.2. If significant XY movement occurred during the image acquisition, align the Z-stack using the ImageJ StackReg plugin (<http://bigwww.epfl.ch/thevenaz/stackreg>).

8.3. Locate the cell (s) of interest.

8.4. Scroll through the XYZ image in the Z direction and identify the optical section that contains the maximal length of the cancer cell blood vessel contact for the cell of interest (**Figure 2E**).

8.5. Measure the cancer cell-blood vessel contact using the “manual length measurement function”.

8.6. Enter the measurements into the data software package that is used for statistical analysis.

NOTE: The ability of cancer cells to attach to the blood vessels can be measured either as the length of cancer cell-blood vessel contacts or the percentage of the cell in contact with the vasculature for particular cancer cell clone (or both).

8.7. Proceed to the next cell of interest.

8.8. Analyze the data for statistical significance comparing mutant clone (s) and control datasets.

## **9. Colony compactness quantification**

9.1. Reinject the cells from the expanded clone using the same technique as in step 2.

9.2. Five days post injection acquire images of 10-50 random metastatic colonies for each clone.

NOTE: No high-quality images are necessary for metastatic colony compactness quantification. Monochromatic, stereo microscope (10x magnification) images are sufficient. Attention should be paid to the brightness of the image (most of the cells within the colony should be seen) and contrast (difference between one or two cells).

9.3. Digitally isolate the colony image (see **Figure 2C,D**) and proceed to colony compactness quantification using the stand-alone colony compactness quantification module or blind scoring.

9.4 Proceed to the next colony of interest.

9.5. Analyze the data for statistical significance comparing mutant clone (s) and control (i.e. scramble shRNA) datasets.

#### **REPRESENTATIVE RESULTS:**

Cancer cell injection is considered to be successful if the majority of the cells that are lodged in the capillaries are single and located at a significant difference from each other (~0.05-0.1 cm) so the colonies will not overlap after 5-6 days of incubation period (**Figure 3A**). The injection was not successful if a buildup of cancer cells can be seen in most of capillaries, embryos displaying this should be discarded (**Figure 2E**). A significant number of injected cancer cells perish within 24 h of injection making some embryos appear to reject all the cancer cells. Cancer cell survival will vary depending on the local egg supplier (i.e., amount of cells to be injected may vary) and we strongly recommend that optimal injection conditions (cancer cell concentration versus injection duration) are determined before proceeding with the experiment. We recommend cell concentration in the range between  $0.5 \times 10^6$  to  $1.0 \times 10^6$  cells/ml. When the optimal cell concentration and duration of injection is achieved, the day 5 post injection transduced cells should produce a wide variety of colony phenotypes with the majority of the colonies appearing invasive as determined by the cancer cells appearing scattered in the CAM tissue (**Figure 3A**). Attention should be paid to the metastatic colonies that appear “compact” and are located far enough from neighboring colonies that they can be excised with forceps and scissors in one piece of CAM tissue (**Figure 3C**). An isolated positive screen hit (i.e., a compact colony) should display the compact colony phenotype upon reinjection (**Figure 3B**). A decrease in cell survival (or cell proliferation rate within the colony) may be observed as well. Therefore, it is possible that higher cell numbers will need to be injected for some of the positive screen hits to obtain enough colony numbers. For measurement of the cancer cell-blood vessel contacts attention should be paid to the vascular wall stain brightness (fluorescent lectin; **Figure 3D,E**) and the appropriate amount of lectin should be injected for the bright/contrast vascular wall signal. Any available image analysis software can be used during the quantification steps after microscope-software calibration has been performed.

#### **FIGURE AND TABLE LEGENDS:**

**Figure 1: Chicken embryo shell-less culture overview.** (A) A weighing dish with lid prepared for shell-less culture. Arrow points to the cut corner. (B) Weighing dishes arranged in rows in the flow hood. (C) Cutting an eggshell with an electric rotary tool. (D) Cracking an egg into a weighing dish. (E) Embryos cultured in the humidified incubator. Scale bars =1 cm (A-D) or 5 cm (E).

**Figure 2: Outline of cancer cell injection and metastatic colony isolation.** (A) Flowchart outlining the chicken embryo screening platform steps. (B) Cancer cell injection set up on the stereo fluorescent microscope stage. (C) Injection of the cancer cells into the CAM vasculature. (D) Image showing successful cancer cell injection (acceptable cancer cell density), taken immediately after injection. (E) Image showing poor cancer cell injection, seen as an over-injected embryo. Note cancer cell build up in the blood capillaries (white arrows). Scale bars = 1 cm.

**Figure 3. Representative results for different steps of the screening protocol.** (A) Metastatic

colonies formed by heterogenous (library transduced cancer cell line HEp3 cells), 5 days post injection. Red arrow shows compact colony (potential positive hit) that should be excised. **(B)** Metastatic colonies formed by one of the isolated screen hits (Kif3b) after reinjection, 5 days post injection. Insets show digitally cut out metastatic colony images from the dashed squares. This is acceptable image quality for C.I quantification. Average C.I. value for hit reinjection (Kif3b) is shown. **(C)** Isolation of the metastatic colony of interest from the CAM tissue. Representative optical sections of **(D)** a control colony, and **(E)** a Kif3b shRNA overexpressing colony, both showing cancer cell-blood vessel contact measurements. CAM vasculature is labeled with fluorescent lectin-649. Scale bars =1 cm (A-C) or 50  $\mu$ m (D, E).

## **DISCUSSION:**

Here we describe a rapid fluorescence microscopy based intravital screening protocol that can be utilized for important applications such as genetic or drug candidate screens. Cancer cells that have been transduced with a genetic library of interest or transfected with individual expression constructs can be rapidly screened and quantified as to phenotype of interest using this chick CAM model. Since transduction or transfection protocols vary significantly, depending on the library type, they are not included in this procedure. Phenotypically relevant metastatic colonies are excised from the CAM, expanded, and DNA isolated for high throughput sequencing to identify the expression construct of interest. Generally, each genetic library is equipped with primer sequences and recommended methods of genomic DNA purification. We recommend using local facility guidelines for the best high throughput sequencing results.

It is recommended to determine the optimal multiplicity of infection (M.O.I.) for a library and cell line before screening. Ideally each cell (and therefore future metastatic colony) should contain only one gene expression construct, however in our experience that is not always achievable. We recommend following the library manufacturer's protocol and testing a wide range of M.O.I. (0.01-5) to achieve as close to 1 as possible. Presence of multiple library expression constructs within each metastatic colony may significantly complicate the colony phenotype analysis. We also recommend using the library manufacturer supplied negative control in your experiments (i.e. scramble shRNA expressing vector that is fluorescently tagged).

Our screening protocol is based on selection of non-invasive fluorescent colonies; it is critical to ensure that all cell lines used in the experiments have similar fluorescence intensity. Uneven fluorescence intensity among the cells (and metastatic colonies) may result in a biased colony selection due to cell or colony brightness instead of invasiveness.

Compared to existing methods our protocol provides several unique advantages such a speed, low cost and ability to complete the intravital screen cycle without need for sophisticated imaging equipment<sup>12-14</sup>. In addition, the whole screening cycle can be completed withing 3 to 6 weeks from the cell injection to sequencing stage. No high-resolution microscope is required for cancer cell injection or metastatic colony isolation as these steps can be performed using basic fluorescent stereo microscope that is available to most researchers. Finally, because shell-less embryo culturing is completely self-sustained there is no need for complicated research animal housing or feeding schedules. Most research institutions do not consider chicken embryos to be

live animals which significantly decreases the cost and documentation burden associated with this model.

However, there are some limitations associated with the shell-less embryo model. First, not all cancer cell lines work in this model efficiently. In our laboratory we routinely use several cancer cell lines, such as HT1080 (human fibrosarcoma), HEP3 (head & neck) and mouse b16 melanoma and 4T1 breast cancer cell lines, that robustly form metastatic colonies when injected into the chicken CAM vasculature. Other cell lines with different cancer types such as breast (MDA468), brain (U87 and U118) or ovarian (A2780s) readily form metastatic colonies when injected into the CAM and therefore can be used in this screening protocol as well<sup>12,14,15</sup>. Yet, in our experience commonly used cancer cell lines such as LnCaP and PC3 do not perform well in this model (unpublished observations). Another limitation is that a confocal microscope with a 100 to 200 µm imaging range is required for high-resolution imaging, such as visualization of cancer cell blood vessel contacts, this equipment may not be available for many researchers.

Altogether, this protocol describes a rapid intravital screening platform that can be used for discovery of cancer metastasis suppressors and drivers. We strongly believe that the robustness and ease-of-use nature of this model will make it an essential screening model for many researchers.

#### **ACKNOWLEDGMENTS:**

This work was supported by Canadian Cancer Society Research Institute Grant #702849 to JDL and KS. Dr. Lewis holds the Frank and Carla Sojonyk Chair in Prostate Cancer Research supported by the Alberta Cancer Foundation.

#### **DISCLOSURES:**


Nothing to disclose.






#### **REFERENCES:**


- 1 Hanahan, D., Weinberg, R. A. Hallmarks of cancer: The next generation. *Cell*. **144** (5), 646-674 (2011).
- 2 Van't Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. *Nature*. **415** (6871), 530-536 (2002).
- 3 Eccles, S. A., Welch, D. R. Metastasis: recent discoveries and novel treatment strategies. *Lancet (London, England)*. **369** (9574), 1742-1757 (2007).
- 4 Weber, G. F. Molecular mechanisms of metastasis. *Cancer Letters*. **270** (2), 181-190 (2008).
- 5 Chambers, A. F., Groom, A. C., MacDonald, I. C. Dissemination and growth of cancer cells in metastatic sites. *Nature Reviews Cancer*. **2** (8), 563-572 (2002).
- 6 Pantel, K., Brakenhoff, R. H. Dissecting the metastatic cascade. *Nature Reviews Cancer*. **4** (6), 448-456 (2004).
- 7 Friedl, P., Wolf, K. Tumour-cell invasion and migration: diversity and escape mechanisms. *Nature Reviews Cancer*. **3** (5), 362-374 (2003).
- 8 Oudin, M. J. et al. Tumor cell-driven extracellular matrix remodeling drives haptotaxis

617 during metastatic progression. *Cancer Discovery*. **6** (5), 516-531 (2016).  
618 9 Leong, H. S. et al. Intravital imaging of embryonic and tumor neovasculature using viral  
619 nanoparticles. *Nature Protocols*. **5** (8), 1406-1417 (2010).  
620 10 Kain, K. H. et al. The chick embryo as an expanding experimental model for cancer and  
621 cardiovascular research. *Developmental Dynamics : An official Publication of the American*  
622 *Association of Anatomists*. **243** (2), 216-228 (2014).  
623 11 Zijlstra, A., Lewis, J., Degryse, B., Stuhlmann, H., Quigley, J. P. The inhibition of tumor cell  
624 intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the  
625 tetraspanin CD151. *Cancer Cell*. **13** (3), 221-234 (2008).  
626 12 Palmer, T. D., Lewis, J., Zijlstra, A. Quantitative analysis of cancer metastasis using an avian  
627 embryo model. *Journal of visualized experiments : JoVE*. (51), e2815 (2011).  
628 13 Stoletov, K. et al. Quantitative in vivo whole genome motility screen reveals novel  
629 therapeutic targets to block cancer metastasis. *Nature Communications*. **9** (1), 2343-2343 (2018).  
630 14 Leong, H. S. et al. Invadopodia are required for cancer cell extravasation and are a  
631 therapeutic target for metastasis. *Cell Reports*. **8** (5), 1558-1570 (2014).  
632 15 Willetts, L., Bond, D., Stoletov, K., Lewis, J. D. in *The Tumor Microenvironment: Methods*  
633 *and Protocols*. Editors: Ursini-Siegel, J., Beauchemin, N. 27-37, Springer New York. (2016).  
634









Name of Material/ Equipment	Company	Catalog Number
1 mL disposable syringes	BD	BD309659
15 mL conical centrifuge tubes.	Corning	CLS430791-500EA
18 gauge x 1 1/2 BD precision nee	BD	BD305196
2.5% Trypsin solution	many sources are available	
4T1 mouse breast cancer	ATCC	CRL-2539
B16F10 mouse melanoma cell line	ATCC	CRL-6475
Benchtop centrifuge.	many sources are available	
Circular coverslips, 22 mm.	Fisher Scientific	12-545-101
Collagenase	Sigma	C0130-100MG
Confocal microscope		
cotton swabs	many sources are available	
Culture media appropriate for the cell lines used	many sources are available	
Egg incubator	many sources are available	
eppendor tubes , 1.5ml	Sigma	T4816-250EA
Fertilized White Leghorn eggs	any local supplier	
	many sources are available	
fine forceps		
Hemocytometer	Millipore-Sigma	MDH-4N1-50PK
HT1080 human fibrosarcoma cell line	ATCC	CCL-121
Image analysis software		
Lectin <i>Lens Culinary</i> Agglutinin (L	Vector Laboratories	RL-1042, FL-1041

MDA-MB-468 human breast cancer	ATCC	HTB-132
PBS (1x)	many sources are available	
Plastic weighting dishes	Simport	CA11006-614
small surgical scissors	many sources are available	
Sodium borosilicate glass capillary tubes, outer diameter 1.0 mm, inner diameter 0.58 mm, 10 cm length	Sutter Instrument	BF100-58-10
Square petri dishes (used as lids for the weighting dishes).	VWR	CA25378-115
Stereo fluorescent microscope		
Tygon R-3603 laboratory tubing	Cole-Parmer	AAC00001
U-118 MG human glioblastoma	ATCC	HTB-15
U-87 MG human glioblastoma	ATCC	HTB-14
Vertical pipette puller	many sources are available	



### Comments/Description

we use 1.2mm x 40mm it is possible to use shorter needles if preferred

Any TC compatible centrifuge that can be used to spin down the cells is suitable

We use Nikon A1r

must be sterilized before use

We grow HT1080, HEp3 and b16 cell lines in DMEM, 10% FBS media

An exact model that is necessary depends on the scale of the screen. Available sources are MGF Company Inc., Savannah, GA, or Lyon Ele

must be sterilized before use

We use Nikon Elements

Dilute stock (5mg/ml) 50-100x depending on the microscope sensitivity. Must be a different color from the color of cell line used for screen

dimensions are 78x78x25mm; many other sources are available

must be sterilized before use

dimensions are 100x100x15mm; many other sources are available

We use Zeiss Lumar v12

1/32 in inner diameter, 3/32 in. outer diameter, 1/32 in. wall thickness

we use David Kopf Instruments, Tujunga, CA; Model 720

etric Company Inc., Chula Vista, CA

ing





**FACULTY OF MEDICINE & DENTISTRY**  
**Department of Oncology**

**John D. Lewis**

*Frank and Carla Sojonyk Chair in Prostate Cancer Research*  
Tel: 780.492.6113  
Fax: 866.426.6697  
jdlewis@ualberta.ca

Katz Group Centre for Pharmacy & Health Research  
114th St and 87th Ave  
Edmonton, AB T6G 2E1 CANADA

November 15, 2020


RE: Manuscript ID JoVE submission JoVE62077revision responses.

Dear Dr. Nam Nguyen,

We are pleased to revise the manuscript according to the recommendations of the editor and reviewers. Please find our responses to the reviewers' comments below.

We thank the reviewers for their thoughtful comments and recommendations. Addressing these requests has greatly improved this manuscript for publication in JoVe.

Sincerely,



John Lewis, Ph.D.

RE: Discovery of Metastatic Regulators Using a Rapid and Quantitative Intravital Chick Chorioallantoic Membrane Model

Konstantin Stoletov<sup>1</sup>, Lian Willetts<sup>2</sup>, Perrin H. Beatty<sup>3</sup> and John D. Lewis<sup>1\*</sup>.

**Editorial comments:**

Changes to be made by the Author(s):

1. Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues. Please define all abbreviations at first use.

*Done*

2. Please revise the following lines to avoid overlap with previously published work: lines: protocol steps 1.2-1.6 (excluding note); note after step 2; 2.8 (depress..buildup).

*We edited these lines to avoid the overlap.*

3. JoVE cannot publish manuscripts containing commercial language. This includes trademark symbols (™), registered symbols (®), and company names before an instrument or reagent. Please remove all commercial language from your manuscript and use generic terms instead. All commercial products should be sufficiently referenced in the Table of Materials and Reagents.

For example: CellTracker; Zeiss Lumar.V12 stereomicroscope; Vectore laboratories; Nikon Elements; Volocity (Perkin Elmer) etc.

*We removed all the commercial product names from manuscript.*

4. Please note that your protocol will be used to generate the script for the video and must contain everything that you would like shown in the video. Please add more details to your protocol steps. Please ensure you answer the “how” question, i.e., how is the step performed? Alternatively, add references to published material specifying how to perform the protocol action. Please add more specific details (e.g. button clicks for software actions, numerical values for settings, etc) to your protocol steps. There should be enough detail in each step to supplement the actions seen in the video so that viewers can easily replicate the protocol.

*We further edited the protocol to make it more suitable for video production expanding some steps description and simplifying the others.*

5. Please convert centrifuge speeds to centrifugal force (x g) instead of revolutions per minute (rpm).

*Corrected.*

6. 1.7: Do you mean  $1 \times 10^6$  cells/mL? Please clarify.

*Corrected.*

7. Note after 4.10: Please cite a reference or provide details about clonal expansion with puromycin.

*This section is now clarified.*

8. 4.12: Please clarify when the need arises to transfer to a larger dish—what confluency of cells, cell morphology etc.

*Clarified.*

9. Representative results: line 331-332: what factors are you referring to when you say “cancer cell survival will vary depending on the local egg supplier”?

*This section is now edited and clarified.*

10. Please include a scale bar for all images taken with a microscope to provide context to the magnification used. Define the scale in the appropriate Figure Legend.

*Scale bars are now added to all images and defined in the figure legends.*

11. As we are a methods journal, please add to the Discussion the following with citations:

a) Any limitations of the technique

b) The significance with respect to existing methods

*This section is now edited to address these comments.*

12. Please ensure that the references appear as the following: [Lastname, F.I., LastName, F.I., LastName, F.I. Article Title. Source. Volume (Issue), FirstPage–LastPage (YEAR).] For more than 6 authors, list only the first author then et al. Please include volume and issue numbers for all references, and do not abbreviate journal names. Capitalize the first letter of all words of the journal names.

*References are edited.*

13. Please sort the Materials Table alphabetically by the name of the material.

*Materials table is edited.*

---

**Reviewer #1:**

**Manuscript Summary:**

Multiple genes and gene sets are involved in upregulating and downregulating the cancer metastatic cascade depending on the cancer type, tissue and individual patient characteristics. The chick CAM (chorioallantoic membrane) intravital human cancer metastasis model is highly effective as a rapid screening platform. Using this model the authors designed a quantitative screening platform that can be used for identification of novel drivers or suppressors of cancer metastasis. They present a rapid screening platform that allows for anti-metastatic target identification and intravital analysis of a dynamic and complex cascade of events. The manuscript describes a protocol that will be of the interest to study metastasis and to find new antitumoral therapies. The efficacy of the protocol has been demonstrated, the authors included several figures and references. I recommend this manuscript for JoVE publication.

**Minor Concerns:**

Materials and Reagents do not list Tumor Cells and culture media as one of the materials. Tumor cells references and source should be included.

*Tumor cell lines are added to Materials and Reagents table.*

Stereo fluorescent microscope, Confocal microscope and Image analysis software data company must be added.

*These items are added to Materials and Reagents table.*

In representative results the quality of the images and text must be improved. For instance, it is not possible to read "length values" in the pics (PDF)

*The images are now improved, larger font size is used.*

**Reviewer #2:**

**Manuscript Summary:**

The protocol described by Stoletov and colleagues provide very useful information on a method to analyze metastasis based on the Chick Chorioallantoic Membrane Model (CAM).

**Major Concerns:**

- There is no explanation regarding how to open the egg shell or how old the chick should be. I would recommend to add this as part of the protocol or, alternatively, refer to another already published protocol.

*A new section (Section 1) describing these steps is now added to manuscript along with a new figure (Figure 1).*

- I consider the point about having the cells labelled with a fluorescent protein very critical (lanes 117-121) and therefore I would suggest to have it at the very beginning of the protocol. Perhaps some suggestions or reference to other papers that used such proteins will be useful as well.

*This part is now moved upwards (lines 144-148) and also mentioned in the Figure 2.*

- Lane 135. The amount of cells is depicted as cells/m. Should that be cells/ml? Please, clarify. Along these lanes it would be important to mention whether a preliminary experiment to optimize the number of cells depending on the cell line used should be develop.

*This section is now edited and clarified (line 167). Also, additional clarification is added to “Representative results” section.*

- In sections 2.9-2.10, starting in lane 183, I would suggest to add more details about how to open and close the egg shell during this process.

*A whole new section (Section1) and a figure (Figure 1) is added to the protocol.*

- Lane 199. How do you identify that the embryo rejected the cancer cells?

*This part is now clarified (lines 246-247).*

- Lane 234. When mentioning the "selection factor", is this referred to the selection antibiotic that confers resistance to the cells when generating stable cell lines containing the fluorescence proteins mentioned at the beginning of the protocol? This has to be clarified.

*This part is now clarified more (lines 296-300).*

Minor Concerns:

- It might be helpful to list at the beginning of the protocol a list of materials that will be required throughout the experiment.

*All the materials are listed in “Materials table” as required by JoVe.*

- Lane 125. In our lab we typically use media to resuspend the cells after trypsinization. The use of PBS here provides any advantage for the cells?

*In our hands, media leads to increased macrophage activation/infiltration. Macrophages are often bright green autofluorescent and interfere with imaging.*

- Lane 245. How many cells are recommended for the sequencing run?

*The approximate number of cells required is now added to protocol (line 306).*

### **Reviewer #3:**

Manuscript Summary:

The egg-Shell less CAM assay has been presented as an attractive model for studying the potential of cancer cells to form metastatic colonies. The method has been used in some other publications of the authors but protocols have never been described in such a Detail. Tumor cells with transduced shRNA library can be injected into the vasculature of the CAM and gen-specific ability to form metastatic colonies can be evaluated. This model can serve as an alternative animal experimental test system. It is fast, less expensive and does not need animal application procedure.

Major Concerns:

line 139: Since the protocol should enable the accurate replication of the method also by researchers that are new in the field, the authors should give more details about the experimental set up (the three references do not give enough Details and have again references to other manuscripts). it is important to describe which developmental day the Experiments starts when it is finished etc.

*The whole new section (Section 1) describing shell-less embryo culture along with a new figure (Figure 1) is now added to the manuscript.*

They have to mention that the CAM model is counting as a non-animal Experiment, give a few Details About regularities for handling chicken Embryos till day 16 in this model which is the last third of development and Embryos receive pain?

*We added a mention in the protocol begging that local regulations must be followed and embryos should be treated in the most humane way possible (lines 107-111).*

lane 135: how to decide if 0.5 or 1Mio cells/ml? Is there a difference in metastatic foci formation? Does the cell number influences the compactness of metastases?

*We clarified why several cell concentrations should be tried at several places in the manuscript now (lines 167-17; 222-227 and 396-403).*

lane 199/331: specify: how it can be detected that Embryos have rejected Cancer cells? could they give a Picture? since it is a crucial Point to recognize correctly.

*This is now clarified (all the cells disappear; lines 246-247).*

lane 222: Transfer in an empty tube or filled with medium or anything else?

*Clarified, the tube must be empty (lines 276-277).*

Did they have ever performed a histological analysis of the metastases (compact or less compact?

*Very valid point. No, histological analysis has not been performed yet but we plan to do it in the near future.*

Literature references could be more actual?

*We re-formatted the literature list as requested.*

Minor Concerns:

in Figure 1A: spelling mistake intravascularily

*Corrected, changed to "i.v."*